Gynoveda — E-Commerce Business Analysis
Report generated: 25 August 2026. Prepared from live website inspection, sitemap analysis, ad-library inspection, CrUX data, and public third-party sources. Confidence levels are noted in brackets where estimates are used.
1. Company Basics
| Field | Detail |
|---|
| Company Name | Gynoveda |
| Website | https://gynoveda.com/ (content + telehealth) · https://shop.gynoveda.com/ (Shopify storefront) |
| Domain | gynoveda.com (registered ~2018–2019) |
| Industry | Women's Health / FemTech / Ayurvedic Consumer Health |
| Sub-category | Ayurvedic fertility, PCOS, menstrual & menopausal wellness (D2C + clinics) |
| Founded | 2019 (seed round 2019; Series A March 2023) |
| Founders | Vishal Gupta (CEO) & Rachana Gupta (husband-wife duo); co-founder Dr. Aarati Patil (gynecologist) |
| Headquarters | Mumbai, Maharashtra, India |
| Company Type | Privately held D2C FemTech; Series A (₹10 crore / $10M round in 2023) |
| Email | No direct email published; "Gynoveda Connect" (business/investment/media) via web form; customer care phone +91 7240000700 |
| Tagline / Positioning | "Ayurveda for Fertility, PCOS, Periods" — "India's #1 Ayurveda brand for Women's Health & Fertility"; "Gynoveda है तो, Good News पक्की है" |
2. What Is Gynoveda?
Gynoveda is a Mumbai-based FemTech company that combines Ayurveda, technology, content, and community to address women's reproductive and gynecological health disorders — from puberty to menopause. Its core conditions are infertility/fertility, PCOS/PCOD, irregular and painful periods, white discharge/intimate health, weight management, and menopause. Unlike a pure supplement brand, Gynoveda operates as a hybrid: it sells Ayurvedic proprietary medicines through a Shopify storefront (shop.gynoveda.com) and runs a growing network of "Ayurveda Fertility Clinics" with in-person doctor consultations, plus a heavy content/SEO engine and a private Facebook community ("Circle of Sisterhood," 1.5 lakh+ members).
Positioning is boldly anti-IVF: marketing explicitly contrasts its "100% Ayurvedic, no side-effects, no surgery, no expensive hormones/IUI/IVF" approach against conventional ART. It brands itself "India's 1st Ayurveda Fertility Clinic for Couples" and claims 20,000 couples have achieved pregnancies. Products are condition-specific "programs" (e.g., a 3-month PCOS 3x program) rather than single SKUs, sold in 1/2/3-month packs with per-tablet pricing transparency.
The brand is celebrity-backed — Taapsee Pannu has been brand ambassador since 2023 — and is widely covered by CNBC, Forbes, Mint, Economic Times, Mid-day, Inc42, YourStory.
3. Founding Journey & Timeline
| Year | Milestone |
|---|
| 2018–2019 | Company founded by husband-wife duo Vishal & Rachana Gupta, with gynecologist Dr. Aarati Patil. Domain registered ~2018; operations from 2019. |
| Oct 2019 | $1M seed round led by Fireside Ventures. |
| 2020–2023 | Tripled revenue year-on-year (FY20→FY23); reached ₹100 crore (~$12M) annual revenue run-rate within 3 years; served 3 lakh (300k) women across 20,000 pincodes. [Medium confidence — from founder statement in ET] |
| Mar 2023 | Raised $10M (₹~83 cr) Series A led by India Alternatives, with Wipro Enterprises, RPG Ventures, Dharampal Satyapal, Alteria Capital, and return investor Fireside Ventures. Total raised ~$11M. |
| 2021 | Times Brand Icon Award 2021. |
| 2022 | "Most Admired D2C Brand of 2022"; Economic Times D2C Ayurveda Brand of the Year. |
| 2023 | Taapsee Pannu becomes brand ambassador. Great Place to Work certified. |
| 2023–2026 | Expanded Ayurveda Fertility Clinic network (Mumbai, Delhi, Pune, Bengaluru, Hyderabad and many tier-2/3 cities via clinic-locator pages); built large city-level IVF-vs-Ayurveda comparison SEO hub. |
| 2026 (current) | ~1,400 active/matched ads in Meta Ad Library; 200+ clinic chain planned over next 3 years (per About page). |
4. Geographic Presence
| Aspect | Detail |
|---|
| HQ | Mumbai, Maharashtra, India |
| Primary Market | India (pan-country, 20,000 pincodes served per founder claim) |
| Physical Locations | "200+ chain of ayurveda fertility clinics planned in the next 3 years" (About page). Active clinic-locator pages exist for Mumbai, Delhi, Pune, Bengaluru, Hyderabad, plus extensive tier-2/3 city IVF-centre comparison pages (Nagpur, Agra, Kanpur, Ahmedabad, etc.). Exact open-clinic count not published. [Low–Medium confidence on current count] |
| Online Reach | Pan-India D2C via shop.gynoveda.com; marketplaces (Amazon, Flipkart, Nykaa). |
| International | No international shipping/marketplace presence confirmed. India-only. |
5. Customer Type
| Segment | Details |
|---|
| Primary | Women aged ~18–45 dealing with PCOS/PCOD, irregular/painful periods, fertility/infertility, white discharge. |
| Secondary | Couples trying to conceive (fertility clinic + "for couples" framing in ads). |
| B2B/Institutional | Not a core model. "Gynoveda Connect" handles business/investment/media; clinic franchise/partnership model implied but not confirmed. |
| Gifting | No gifting line confirmed. |
| Demographics | Predominantly Indian women; Hindi + English bilingual marketing (heavy Hinglish ad copy). Mass-premium, value-conscious but willing to pay for "natural/curative" outcomes. |
5a. Audience Device Composition (CrUX Form Factors)
Data source: Chrome User Experience Report (CrUX), origin https://gynoveda.com/, extracted 25 Aug 2026. Latest period as of 2026-08-22.
Device Split Overview
| Metric | Value |
|---|
| Latest Period | 2026-07-26 – 2026-08-22 |
| Phone | 93.2% |
| Desktop | 6.78% |
| Tablet | 0.00% |
| Mobile:Desktop Ratio | 13.7:1 |
| Primary Device | Phone (overwhelmingly mobile) |
Recent Trend (8-week)
| Period | Phone | Tablet | Desktop |
|---|
| 2026-07-05 – 2026-08-01 | 92.7% | 0.00% | 7.27% |
| 2026-07-12 – 2026-08-08 | 93.2% | 0.00% | 6.85% |
| 2026-07-19 – 2026-08-15 | 93.1% | 0.00% | 6.94% |
| 2026-07-26 – 2026-08-22 | 93.2% | 0.00% | 6.78% |
(Full 45-week series available; phone share has been stable in the 91.8%–94.1% band across the entire Oct 2025–Aug 2026 window, with desktop creeping from ~6.0% to ~6.8%.)
Key Findings
- Dominant device: Phone at 93.2% — an extreme mobile-majority audience, typical of consumer health/femtech in India where access is smartphone-first.
- Trend direction: Flat. Phone share has not moved meaningfully in 10 months (±1.5pp), so this is a structural, stable audience rather than a campaign spike.
- B2B signal: Desktop at <7% rules out any meaningful B2B/professional-buyer segment — traffic is pure consumer.
- Tablet: 0.00% consistently — negligible, as expected for this category.
- Implication: Mobile-first is non-negotiable. Prioritize thumb-friendly CTAs, fast LCP on phones (CrUX shows LCP ~1.7s — already good), and mobile ad formats (the Meta ads observed are vertical video). Desktop experience matters for <7% of users but the clinic/appointment funnel (forms) must still be flawless on mobile.
6. Founders & Team
| Field | Detail |
|---|
| Founders | Vishal Gupta (Co-founder & CEO) — previously in consumer/health; Rachana Gupta (Co-founder); Dr. Aarati Patil (Co-founder, gynecologist, editorial-policy author on site). |
| Founder Background | Husband-wife operator team + clinical co-founder. Vishal is the public face (quoted in funding/PR). |
| Employee Count | 51–200 per Tracxn/company databases. [Medium confidence] |
| Hiring Activity | "200+ clinics planned" implies active clinic-ops, doctor, and city-expansion hiring; specific open roles not enumerated in this pass. |
7. Revenue & Financials
| Aspect | Detail |
|---|
| Revenue (exact) | Not publicly disclosed as audited figure. |
| Estimated Revenue | ₹100 crore (~$12M) annual revenue run-rate claimed by founders (FY23). [Medium confidence — founder statement, not audited] |
| Revenue Growth | "Tripled year-on-year between FY20 and FY23" (founder statement). [Medium confidence] |
| E-commerce Revenue Share | Not disclosed. Blend of D2C Shopify, marketplaces, and clinic consultations/Programs. |
| Funding Status | Series A closed Mar 2023: $10M led by India Alternatives; total raised ~$11M incl. $1M seed (2019). Investors: India Alternatives, Wipro Enterprises, RPG Ventures, Dharampal Satyapal, Alteria Capital, Fireside Ventures. |
| Authorized Capital | Not publicly available. |
8. Business Model
| Stream | Description |
|---|
| D2C Product Sales | Ayurvedic condition-specific "programs" (tablets) sold on shop.gynoveda.com in 1/2/3/4-month packs. Core revenue engine. |
| Marketplaces | Amazon, Flipkart, Nykaa listings extend reach (per Indian Retailer / marketplace search). |
| Clinic Consultations | "Ayurveda Fertility Clinic" network — doctor consultations, in-person + tele-consult (book-appointment). Higher-ticket, recurring. |
| Content + SEO Funnel | Massive blog/comparison hub (IVF-vs-Ayurveda, city clinics, condition articles) drives organic acquisition; calculators & "fertility test" capture leads. |
| Community (Circle of Sisterhood) | 1.5 lakh+ member private FB group → retention, UGC, referral, brand trust. |
| Brand (Licensing/Influencer) | Taapsee Pannu ambassadorship; PR-driven credibility. |
9. Manufacturer or Reseller?
Manufacturer / owned brand. Gynoveda sells its own proprietary Ayurvedic formulations ("India's 1st PCOS 3x Ayurvedic Program"), certified by the US FDA and India's NABL (National Accreditation Board for Testing and Calibration Laboratories) per company PR. Products are branded (Boost Fertility, Tula, Veera, Soma, Jeehv, etc.) and not third-party resale. It is a vertically integrated D2C Ayurveda brand, not a marketplace reseller. [High confidence — stated on site + corroborated by ET/Indian Retailer]
10. Physical Store vs. Online Focus
| Channel | Est. Revenue Share | Details |
|---|
| D2C Website (Shopify) | Largest | shop.gynoveda.com; condition-based programs; full catalog. |
| Marketplaces | Meaningful | Amazon, Flipkart, Nykaa confirmed. |
| Physical Clinics | Growing | "200+ clinics planned"; current open count not published but active across major metros + tier-2/3. |
| B2B/Institutional | Minimal | Not a focus; "Gynoveda Connect" for business/media only. |
11. Price Tier
| Category | Price Range (INR) | Positioning |
|---|
| Entry nutrition (Iron Folic Acid) | ₹469–844 | Accessible entry |
| Single-condition programs (Tula/Soma/Veera) | ₹1,313–3,281 | Mid |
| Combo/PCOS 3x programs | ₹1,875–7,500 | Mid-premium (3–6 bottle packs) |
| Fertility/Jeehv/Menopause | ₹2,063–4,125 | Mid-premium |
| Diet book | ₹499 (free in some clinic flows) | Low/lead-gen |
Overall: Mass-premium Ayurvedic wellness. Per-tablet transparency (₹4–₹18/tablet) positions against expensive IVF (ads explicitly contrast "bine mehenge IUI, IVF"). Multi-month packs reward commitment; "Big Saving" and "Bestseller" badges drive the 3-month default.
12. Products & Categories — Full Catalog
Gynoveda's Shopify store lists 12 products (sitemap_products) across condition categories. Collections: PCOS, Menstrual, Fertility, Wellness, Skin Care, Wellness-care, Offers/Deals, All.
| # | Category | Products | SKU Count |
|---|
| 1 | PCOS / PCOD | pcos-pcod (delayed), pcos-pcod-heavy-flow, pcos-pcod-regular | 3 |
| 2 | Periods / Menstrual | tula (irregular), veera (heavy flow) | 2 |
| 3 | Fertility | fertility-support, jeehv | 2 |
| 4 | Intimate Health | soma (white discharge) | 1 |
| 5 | Menopause | ayurvedic-menopause-tablets | 1 |
| 6 | Nutrition | iron-folic-acid | 1 |
| 7 | Content/Books | gynovedic-diet-book (+ VC-clinic-free variant) | 2 |
Total SKU Count: 12 products (Shopify sitemap). Note: several are format variants of the same formulation (e.g., 2 diet-book variants; jeehv ≈ fertility-support).
Hero / Best-Sellers (homepage-featured)
- Boost Fertility (Jeehv) — ₹2,063; 4.8–4.9★ — improve egg quality, healthy pregnancy.
- PCOS, PCOD (3x Program) — ₹2,400 / up to ₹4,219; 4.6–4.9★ — reverse PCOS, on-time cycles.
- Delayed Periods, Less Flow (Tula) — ₹1,400; 4.8★.
- Early Periods, Heavy Flow (Veera) — ₹1,400; 4.5★.
- White Discharge (Soma) — ₹1,400; 4.7★.
- Menopause — ₹1,050; 4.6★.
(Note: homepage shows rounded display prices; Shopify JSON shows exact variant pricing in pricing-data.csv.)
13. Product-Market Fit Signals
| Signal | Evidence |
|---|
| Strong ratings | All products show 4.5–4.9★; ~2,495 reviews aggregated on store. |
| High review volume | 27,433+ Google Reviews (4.7★) cited on site; ~1,400 active Meta ads suggest sustained demand. |
| Community scale | 1.5 lakh+ member private Facebook group ("Circle of Sisterhood"). |
| Clinical + D2C hybrid | 200+ clinics planned; appointment booking live — validates trust-led model. |
| Organic dominance | 882 URLs in main sitemap; huge city/condition SEO hub → strong top-of-funnel demand capture. |
| Celebrity endorsement | Taapsee Pannu (2023–) + Tier-1 PR coverage. |
14. Major Catalog Gaps
| Gap | Opportunity | Effort | Impact | Realistic for Brand? |
|---|
| No subscription / auto-replenish | Ayurveda is a 3–6 month commitment; a subscribe-&-save would lift LTV and reduce churn. | Medium | High | Yes — natural fit; Shopify supports it. |
| Thin SKU breadth vs. claim of "women's health from puberty to menopause" | Expand into sexual-health, libido, thyroid, post-partum, endometriosis, hair/skin (a "skin-care" collection exists but is sparse). | Medium | Medium | Yes — brand has authority to extend. |
| No quick-commerce (Blinkit/Zepto/Swiggy Instamart) presence | FMCG/wellness buyers expect 10-min delivery for replenishment; competitors in wellness increasingly there. | Medium | Medium | Partially — depends on margin/MOQ; worth a pilot. |
| No international shipping | Large diaspora demand (US/UK/AU desi women). | High | Medium | Maybe later — regulatory (FDA/AYUSH) complexity. |
| Gifting / trial sachet line | Lower-friction first purchase; referral hooks. | Low | Medium | Yes — cheap to test. |
| Language localization beyond Hinglish | Regional-language pages (Marathi, Tamil, etc.) given pan-India, tier-2/3 reach. | Medium | Medium | Yes — aligns with clinic expansion. |
15. Reviews & Product Quality Signals
| Source | Signal |
|---|
| Website/Store Reviews | ~2,495 reviews; products 4.5–4.9★. Thimatic/WC review app. |
| Google Reviews | 27,433+ reviews, 4.7★ (cited site-wide). |
| Quality Claims | Proprietary Ayurvedic formulations; US FDA + NABL certified (per PR). "No side-effects" messaging. |
| Common Praise | Pregnancy/PCOS success stories; natural approach; doctor-backed. |
| Common Complaints | Not directly sampled this pass; typical category risks = time-to-result (Ayurveda needs 3+ months), taste, and refund friction. Returns/Refunds policy page exists. |
16. Digital Channel Presence & Stats
| Platform | Presence | Details |
|---|
| D2C Website | ✅ | gynoveda.com (Next.js content/telehealth) + shop.gynoveda.com (Shopify storefront) |
| Amazon | ✅ | Listed (per Indian Retailer); specific store page not captured. |
| Flipkart | ✅ | Brand store present (health-care/ayurvedic/gynoveda). |
| Nykaa | ✅ | Brand page nykaa.com/brands/gynoveda/c/21922. |
| Blinkit (Quick Commerce) | ❌ | Not confirmed. |
| Zepto | ❌ | Not confirmed. |
| Swiggy Instamart | ❌ | Not confirmed. |
| BigBasket | ❌ | Not confirmed. |
| Mobile App | ❌ | No iOS/Android app detected; web-only + FB community. |
| YouTube | ✅ | @Gynoveda — 78K subscribers, 793 videos. |
| Meta Ads | ✅ | ~1,400 active/matched ads (India), video, city-specific, since May 2026. |
Website Tech Stack
| Component | Technology |
|---|
| Main site (gynoveda.com) | Next.js (React SSR), served via Envoy proxy; custom CMS for content/SEO/clinic locator. |
| Shop subdomain (shop.gynoveda.com) | Shopify (shopify-complexity-score 113; cdn.shopify.com; _shopify_y cookies). |
| Theme / Apps | Shopify theme (t/241); Thimatic product-reviews app; Owl Carousel, Swiper, Magnific Popup. |
| CDN | Shopify CDN (products); Cloudflare referenced on shop. |
| Payment | Razorpay-class Indian gateway expected (not directly observed); COD likely on marketplaces. |
| Hosting/Security | Envoy front; HSTS, CSP (frame-ancestors none), X-Frame-Options DENY on shop. |
Website Age / Last Redesign
- Domain registered ~2018; active since 2019. Last sitemap modification 2026-08-24 (daily cadence). Next.js SPA suggests a recent modern rebuild (webp hero assets, app-like UX).
17. Social Media Presence
| Platform | Handle (actual URL) | Follower Count | Notes |
|---|
| Instagram | https://www.instagram.com/gynoveda/ | (not accessible) | Hard login wall — full redirect, no content behind. Count not extractable. |
| Facebook | https://www.facebook.com/gynoveda/ | (not accessible) | Hard login wall — full redirect. Count not extractable. |
| LinkedIn | https://in.linkedin.com/company/gynoveda | (not extracted) | Company page exists (footer). |
| YouTube | https://www.youtube.com/@Gynoveda | 78K subscribers | 793 videos; branded channel. [Verified via /about] |
| TikTok | — | — | No handle found. |
| Pinterest | — | — | No handle found. |
| X/Twitter | — | — | No handle found in footer or search. |
Circle of Sisterhood (private Facebook group): 1.5 lakh+ (150,000+) members — the brand's flagship owned community, cited on the contact page.
Note: Instagram and Facebook are full login-redirect walls; follower counts could not be retrieved despite attempts. YouTube was accessible and verified at 78K subscribers.
18. Estimated Ad Spend
| Channel | Est. Monthly Spend | Methodology |
|---|
| Meta (Instagram/Facebook) | ₹25–60 lakh / mo (~$30K–70K) | ~1,400 active/matched ads in Meta Ads Library (India), video creative, city-level campaigns (Mumbai, Kolkata…) running since May 2026. At ~₹150–400 CPM video + broad reach, a 1,400-ad footprint implies sustained mid-to-high six-figure INR monthly. Range reflects uncertainty in CPM/audience. [Low–Medium confidence] |
| Google Ads | Not measured | Google Ads Transparency not queried this pass; strong SEO suggests some paid-search likely on "PCOS treatment"/"fertility" keywords. |
| Amazon/Marketplace Ads | Likely active | Present on Amazon/Flipkart/Nykaa; sponsored placements probable but not quantified. |
| Influencer/Creator | Moderate | Taapsee Pannu ambassadorship + doctor/community UGC; creator spin likely. |
| Total Estimated | ₹30–70 lakh / mo (~$35K–85K) | Dominated by Meta video; range, not a point estimate. |
Methodology note: Scale inferred from observable Meta Ad Library footprint (count, geo, duration), not from a self-reported budget. Actual spend could be higher given clinic-expansion ambitions.
19. Competitors
Direct Competitors
| Competitor | Overlap Area |
|---|
| Niramai / Ayushman / other Ayurvedic women's health D2C (e.g., Himalaya Wellness Women's range, Baidyanath Stree Rasayan) | Ayurvedic PCOS/period/fertility formulations. |
| Pee Safe / Sirona (intimate & menstrual wellness) | Intimate health, period care (though more OTC than curative). |
| Lybrate/Practo + Ayurvedic tele-clinics | Tele-consult + condition content. |
| Modern IVF/ART chains (Apollo Fertility, Nova, Indira IVF) | Explicitly positioned against these ("no expensive IUI/IVF"). |
Tertiary / Adjacent
| Competitor | Overlap Area |
|---|
| Traya Health (hair/PCOS holistic) | Holistic PCOS programs. |
| The Himalayan Organics / Medikonda (marketplace Ayurvedic) | Marketplace SKU competition (per EasyLeadz). |
| Mylo / Pristyn / manifiest wellness apps | Women's health content + community. |
(Source: Tracxn lists 59 active competitors in the Ayurvedic FemTech space, 4 funded, 3 exited.)
20. Market Position
| Aspect | Position |
|---|
| Segment | Ayurvedic FemTech / women's reproductive health. |
| Rank | Claims "India's #1 Ayurveda brand for Women's Health & Fertility"; credible category leader in Ayurvedic fertility. [Brand claim] |
| Differentiation | Clinic + D2C + community + content loop; anti-IVF narrative; FDA/NABL-certified proprietary meds. |
| Market Share | Not disclosed; among the best-funded Ayurvedic women's-health D2C players. |
| Brand Perception | Clinical-credible, natural, outcome-driven, celebrity-validated. |
21. Key Differentiators
- Hybrid clinic + D2C model — only Ayurvedic women's-health brand pairing proprietary meds with a physical "Ayurveda Fertility Clinic" network and doctor consults.
- Condition-specific "programs," not pills — 3–6 month outcome framing with per-tablet pricing transparency.
- Anti-IVF narrative — clear, emotive positioning ("Gynoveda है तो, Good News पक्की है") vs. expensive, invasive ART.
- Community moat — 1.5 lakh+ member "Circle of Sisterhood" private group drives trust and retention.
- Content/SEO engine — 882-URL sitemap, city-level IVF-vs-Ayurveda comparison hub captures high-intent top-of-funnel.
- Clinical credibility — gynecologist co-founder (Dr. Aarati Patil), FDA/NABL certification claims, Taapsee Pannu ambassadorship, Tier-1 PR.
- Heavy video ad presence — ~1,400 Meta ads, city-segmented, Hindi/English, since 2026.
22. Category Tailwinds
| Trend | Impact on Gynoveda |
|---|
| Rising PCOS/infertility awareness in India | Expands TAM; high-intent demand. |
| "Natural / Ayurvedic / no side-effects" preference | Core to brand; tailwind vs. pharma. |
| IVF cost sensitivity | Anti-IVF narrative converts priced-out couples. |
| FemTech investment boom | Funding access; validates category. |
| Creator/community commerce | Circle of Sisterhood + ambassador amplify CAC efficiency. |
| Women's health content consumption (Hinglish video) | Feeds Meta video ad engine + YouTube (78K). |
23. PR Mentions, Awards & Collaborations
| Type | Details |
|---|
| Awards | Times Brand Icon Award 2021; Most Admired D2C Brand 2022; Economic Times D2C Ayurveda Brand of the Year; Great Place to Work certified. |
| Press Coverage | CNBC, Forbes, Mint, Mid-day, Economic Times, Inc42, YourStory, Entrepreneur (logo wall on homepage/about). |
| Collaborations | Taapsee Pannu — brand ambassador since 2023. Investors: Wipro Enterprises, RPG Ventures, India Alternatives, Fireside, Alteria, Dharampal Satyapal. |
| Founder Media | Vishal Gupta is an active spokesperson (quoted in ET, Entrepreneur, YourStory). |
24. Hiring Activity
| Detail | Info |
|---|
| Open Positions | Not enumerated this pass; "200+ clinics planned in 3 years" signals clinic-ops, medical, city-launch, and D2C/marketing hiring. |
| Departments Hiring | Implied: Clinical/Doctors, Clinic Ops, Growth/Performance Marketing, Content, Engineering. |
| Office Locations | Mumbai HQ; clinics across metros + tier-2/3. |
| Growth Signals | Series A funded; aggressive clinic-expansion roadmap; ~1,400 live ads. |
25. SWOT Summary
| Positive | Negative |
|---|
| Internal | Strong brand + celebrity + clinical credibility; hybrid clinic/D2C/community moat; funded ($11M); 4.7★/27K reviews; category-leading content SEO. | Thin SKU count (12); no subscription/replenish; no quick-commerce; no app; clinic count unproven vs. 200+ ambition; limited social transparency (IG/FB login-walled). |
| External | Large, growing Ayurvedic women's-health TAM; anti-IVF tailwind; FemTech funding climate; community-commerce rise. | Intense competition (IVF chains, Himalaya, D2C wellness); long Ayurveda time-to-result risking refunds; regulatory (FDA/AYUSH) scrutiny; Meta ad-cost inflation. |
26. Citations
- https://gynoveda.com/ — homepage, hero, product cards, social links, Google review count
- https://gynoveda.com/pages/about/ — founders, 2019 founding, $10M funding, 200+ clinics plan, Taapsee Pannu, Circle of Sisterhood, awards
- https://gynoveda.com/pages/contact/ — phone +91 7240000700, Circle of Sisterhood 1.5Lakh+ members, social links
- https://shop.gynoveda.com/ — Shopify storefront (tech stack via headers)
- https://shop.gynoveda.com/sitemap_products_1.xml — 12 product SKUs
- https://shop.gynoveda.com/products/*.json — exact variant pricing, per-tablet cost, review counts
- https://www.youtube.com/@Gynoveda/about — 78K subscribers, 793 videos
- https://www.facebook.com/ads/library/?q=Gynoveda&country=IN — ~1,400 active/matched ads, city campaigns since May 2026
- https://economictimes.indiatimes.com/tech/funding/ayurveda-brand-gynoveda-raises-10-million/articleshow/98640413.cms — $10M Series A, investors, ₹100cr run-rate, 3 lakh women
- https://www.indianretailer.com/news/wipro-consumer-care-invests-womens-healthcare-brand-gynoveda — marketplace presence (Amazon/Flipkart/Nykaa), FDA/NABL certification
- https://www.nykaa.com/brands/gynoveda/c/21922 — Nykaa brand page
- https://www.flipkart.com/health-care/home-medicines/lifestyle-disorders/ayurvedic/gynoveda~brand/pr — Flipkart brand listings
- https://tracxn.com/d/companies/gynoveda/ — funding ($10.9M), 59 competitors, team size 51–200
- https://www.statshow.com/www/gynoveda.com — global rank #89,563; ~159,870 monthly visitors; ~351,720 monthly pageviews
- https://cruxvis.withgoogle.com/#/ (origin gynoveda.com) — CrUX form factors: 93.2% phone / 6.78% desktop / 0% tablet as of 2026-08-22
Confidence legend: [High] directly observed or authoritative; [Medium] inferred from multiple indirect signals; [Low] rough estimate. Social follower counts for Instagram/Facebook are unavailable due to login walls and are explicitly left blank rather than guessed. Revenue and headcount figures are founder/third-party statements, not audited.